Sophie Allauzen
Consultant / Advisor chez Adjuvant Capital LP
Profil
Dr. Sophie Allauzen has 20 years of international experience in R&D, business development, and portfolio management in various diagnostic industries managing the full life-cycle of novel diagnostic products (R&D, planning, commercialization, and registration) in developed and developing worlds.
Sophie’s experience includes the Bill & Melinda Gates Foundation where she oversaw malaria and a portfolio of neglected diseases diagnostic programs, Novartis Diagnostics as Head of Blood Testing running the NAT/Immunohematology product portfolio, and Bio-Rad managing the R&D department for the development of bead multi-array immuno-assays.
Prior moving to the U.S., Sophie spent five years at Sanofi Diagnostics Pasteur in France, in R&D working on the development of various tests for infectious diseases.
Sophie holds a PhD in biochemistry/immunology from Montpellier University, France, directed toward auto-immune disease mechanisms, and completed her postdoc fellow position in allergy at University of Minnesota.
She is currently an independent consultant based in San Francisco, CA.
Postes actifs de Sophie Allauzen
Sociétés | Poste | Début |
---|---|---|
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | Consultant / Advisor | - |
Formation de Sophie Allauzen
Université de Montpellier | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | Finance |